AUAUniversity

Novel Imaging for High Risk Prostate Cancer Podcast (2021) CME Available: auau.auanet.org/node/33480 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.

Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer Podcast (2021) CME Available: auau.auanet.org/node/33472 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.

Identification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer Podcast (2021) CME Available: https://auau.auanet.org/node/33476 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.

Role of Genetic Testing in Advanced M1 CRPC & M1 CPRC Post-docetaxel, Neuroendocrine Cancer and End of Life Care Presented by Leonard Gomella, MD and Joshua Lang, MD https://auau.auanet.org/node/34071 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme

Optimizing the Treatment of Complicated UTIs CME Available: https://auau.auanet.org/node/33500 ACKNOWLEDGEMENT: This activity is supported by an independent educational grant from Spero Therapeutics.

Early M1 CRPC & Advanced M1 CRPC Presented by Kelly Stratton, MD and Deborah Kaye, MD CME Available: https://auau.auanet.org/node/34065 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme

Advances in Immuno-Oncology in Urothelial Carcinoma Podcast (2021) CME Available: https://auau.auanet.org/node/33484 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.

BCR and Novel Pet Imaging & M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD CME Available: https://auau.auanet.org/node/34059 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme

This podcast was funded by and developed in collaboration with Boston Scientific

CME Available: https://auau.auanet.org/node/33094 Acknowledgements This educational activity is supported by an independent educational grant from: Urovant

CME Available: https://auau.auanet.org/node/33093 At the conclusion of the activity, participants will be able to: 1. Describe recent developments in the medical management of advanced prostate cancer. 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Discuss clinical investigations in the treatment of advanced prostate cancer. 4. Analyze...

NMIBC Guidelines by American Urological Association

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc. CME Available: auau.auanet.org/node/31819 At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinician comm...

Urolithiasis: Metabolic Evaluation and Medical Management by American Urological Association

Optimizing Pre-Operative Care for Patients Undergoing Urologic Surgery by American Urological Association

Reducing Opioid Exposure in the Perioperative Setting by American Urological Association

This podcast was funded by and developed in collaboration with AstraZeneca. Learning Objectives: At the conclusion of this activity, participants will be able to: 1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy. 2. Evaluate available clinical safety and efficacy data for PARP Inhibitors. 3. Describe indications and contraindic...

This podcast was funded by and developed in collaboration with AstraZeneca. Learning Objectives: At the conclusion of this activity, participants will be able to: 1. Identify the role of genomic testing in men with different stages of prostate cancer. 2. Recognize the need for collaboration with genetic counselors for optimal genetic evaluation tailored to an individual prostate cancer patient. 3....

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc. CME Available: https://auau.auanet.org/node/31815 At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinic...

This educational series is supported by independent educational grants from Olympus Corporation of the Americas and Teleflex. CME Available: https://auau.auanet.org/node/32295 At the conclusion of this activity, participants will be able to: 1. Describe the role of the AUA Clinical Guidelines for the Surgical Management BPH. 2. Discuss the evidence base for current technologies, including pivotal...

Designed to encourage high quality, evidence-based testing and care of patients with bladder cancer, this podcast episode focuses on Genetic Testing for Bladder Cancer. Listen today to discover the differences between molecular markers and genetic testing, how genetic testing for bladder cancer is performed and current considerations of genetic findings. Co-Host: Neal Shore, MD, FACS Acknowledgeme...

Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2021) CME Available: https://auau.auanet.org/node/31460 ACKNOWLEDGEMENTS Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc. At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences betw...

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021) CME Available: https://auau.auanet.org/node/31450 ACKNOWLEDGEMENTS Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme. At the conclusion of the a...

Trimodality Therapy for Management of Muscle Invasive Bladder Cancer (2021) CME Available: https://auau.auanet.org/node/31470 ACKNOWLEDGEMENTS Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck. At the conclusion of the activity, participants will be able to: 1. Demonstrate an understanding of prospective randomized trials and large institutional ex...

Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2021) CME Available: https://auau.auanet.org/node/31465 ACKNOWLEDGEMENTS Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck. At the conclusion of the activity, participants will be able to: 1. Differentiate among the subtypes of kidney cancer, with emphasis on clinic...